DAY ONE

DAY TWO

Day One: Tuesday September 13, 2016

Online Agenda

REGISTRATION & COFFEE

7:30

8:15

Introduction: An Overview of the History of the Development of Targeted Therapies for Lung Cancer

 

Nagla Abdel Karim

Associate Professor of Medicine

 

University of Cincinatti Cancer Institute

Antibody Drug Conjugates for Lung Cancer

8:30

TBC

 

Lioudmila Tchistiakova

Senior Director, Global Biotherapeutic Technologies

 

Pfizer

 

9:00

Safety and efficacy of single-agent Rovalpituzumab Tesirine, a delta-like protein 3 (DLL3)-targeted ADC in recurrent or refractory small cell lung cancer

 

Scott Dylla

Chief Scientific Officer, Vice President of R&D

 

Stemcentrix

9:30

Development of Probody™ Therapeutics and Probody Drug Conjugates (PDCs) with potential for the treatment of lung cancer

 

Jon Terrett

Vice President, Oncology

 

CytomX

10:00

Targeted Small Molecule Drug Conjugates and Companion Imaging Agents for Personalized Lung Cancer Therapy

 

Chris Leamon

Vice President, Research

 

Endocyte

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

11:20

TBC

 

 

Carol Pena
Director, Global Biomarkers, US Representative

Bayer

11:50

Spotlight: A precise companion tool from discovery to market

 

 

Jianfu Wang
Chief Executive Officer

Novodiax

12:00

Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins

 

 

James Prudent

Chief Executive Officer

 

Centrose

LUNCH & NETWORKING

12:30

Immunotherapies in Lung Cancer

1:30

Immunotherapy Combinations: An Overview

 

 

Justin Gainor

Instructor in Medicine

 

Massachusetts General Hospital

2:00

PD-L1 Biomarkers for Anti-PD-1/PD-L1 in lung cancers

 

 

Rakesh Dixit

Vice President, R&D; Global Head Biologics Safety Assessment, Pathology and LAR

 

MedIummune

2:30

Title TBC (PD-1 inhibition for lung cancer treatment)

 

 

Reshma Rangwala

Senior Principal Scientist - Oncology

 

Merck

AFTERNOON REFRESHMENTS & NETWORKING

3:00

3:30

Therapeutic strategy against tumor acidity induced immune-suppression: L-DOS47 a clinical candidate for lung cancer

 

Heman Chao

Chief Scientific Officer

 

Helix Biopharma

4:00

Design of Multispecific Antibodies - Modulating T-Cell Functions for Redirected Cytotoxicity

 

Matt Staron

Senior Scientist II, Biologics / Cancer Immunotherapy

 

abbvie

4:30

Overriding immune Suppression and Increasing TILs Through Blockade of the Phosphatidylserine Signaling Pathway

 

Jeff Hutchins

 

Vice President, Pre-Clinical Research

 

Peregrine

Cancer Vaccines

5:00

ADXS-NEO in Lung Cancer

 

Robert Petit

Chief Scientific Officer

Advaxis

5:30

Title TBD: TG4010 cancer vaccine

 

Hemanshu Shah

Vice President, Corporate Development & Medical Affairs

 

Transgene

SUMMARY & CLOSE OF DAY ONE

6:00

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2017| All content produced by: neo-synth ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF